What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? [electronic resource]
Producer: 20080529Description: 816-21 p. digitalISSN:- 1522-726X
- Angioplasty, Balloon, Coronary -- adverse effects
- Anticoagulants -- therapeutic use
- Aspirin -- therapeutic use
- Cardiovascular Diseases -- etiology
- Clopidogrel
- Fibrinolytic Agents -- adverse effects
- Hemorrhage -- chemically induced
- Heparin -- therapeutic use
- Hirudins
- Humans
- Myocardial Infarction -- mortality
- Patient Selection
- Peptide Fragments -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Practice Guidelines as Topic
- Randomized Controlled Trials as Topic
- Recombinant Proteins -- therapeutic use
- Research Design
- Stents
- Thrombin -- antagonists & inhibitors
- Thrombosis -- etiology
- Ticlopidine -- analogs & derivatives
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.